ClinicalTrials.gg
RecruitingNCT06805773Updated Oct 14, 2026

Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic

An interventional study of Educational videos and Standard of Care in Sarcoma, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Mount Sinai Hospital, Canada · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Sarcoma with a site in Canada — 21 open to participants now, 40 under way, 2 of them phase 3. Sarcoma · Canada.

Planned enrollment
53rd of 125
100 · median 71
Started
2025
with 8 others
No phase
13 of 145
5 open now
Primary completion
2027-12
later than 23 of 39 live
Registered
135th of 145
by date
Lead sponsor
3 of 145
Mount Sinai Hospital, Canada

Among the 145 studies in Sarcoma with a site in Canada, this one is the 53rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2025, is one of 13 with no phase, reaches primary completion later than 23 of the 39 other live ones, and was the 135th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

21 of the 145 studies in Sarcoma with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Sarcoma with a site in Canada, or all of them as a file.
02

Study summary

This study aims to evaluate how sarcoma-specific educational videos improve patients' knowledge of their disease and treatment options before their first clinic appointment.

Participants will watch four educational videos before their first appointment with a medical oncologist. Participants will be asked to complete surveys to assess their understanding of sarcoma and its treatment options before and after their first medical oncology clinic appointment.

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • Education
  • Sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written and voluntary .
  2. Have documented advanced sarcoma, or is a caregiver of a patient with histologically documented advanced metastatic sarcoma.
  3. Age ≥ 18 years.
  4. Have not received any previous systemic treatment for sarcoma, or is a caregiver of a sarcoma patient who has not received any previous systemic treatment for sarcoma.
  5. Willing/able to complete questionnaires.
  6. Able to read and write in English.

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide .
  2. Previously seen by a medical oncologist for their sarcoma.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Educational Videos

    Other: Educational videos

  • Other
    Standard of Care

    Other: Standard of Care

Interventions

  • OtherEducational videos

    Participants will be provided with four educational videos in clinic prior to their initial medical oncology consult.

  • OtherStandard of Care

    Participants in the control arm will be provided with the educational videos after their consult with the medical oncologist.

06

What researchers measure

Primary outcomes

  1. Assess differences in patients' and caregivers' knowledge and perceptions of sarcoma and its treatment before and after educational intervention

    Evaluate the changes in global responses between baseline surveys and post educational intervention surveys.

    Time frame: up to 2 weeks (date when given appointment and date of first appointment)

Secondary outcomes

  1. Assess understandability and actionability of sarcoma educational videos.

    The Patient Education Materials Assessment Tool (PEMAT) for Audiovisual Materials will be used to assess the video's understandability and actionability. The higher the score (\>80%), the more understandable or actionable the material.

    Time frame: up to 2 weeks (date when given appointment and date of first appointment)

  2. Assess understandability and actionability of sarcoma educational videos.

    The Suitability Assessment of Materials (SAM) will be used for evaluation of health-related information for adults to objectively assess the suitability of these educational materials for sarcoma patients.

    Time frame: up to 2 weeks (date when given appointment and date of first appointment)

  3. Assess patient's and caregivers' satisfaction with the educational videos

    Based on responses from a post-educational intervention survey. The scores will be measured using a Likert Scale (1-5), with higher scores indicating greater satisfaction.

    Time frame: up to 2 weeks (date when given appointment and date of first appointment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Murtas F, Matharu J, Domlog M, Lawrie K, Salawu A, Gupta A, Deng Y, Avery L, McDonald M, Toor H, Papadakos J, Razak ARA, Watson GA. Evaluating the Feasibility of Educational Videos in a Medical Oncology Sarcoma Clinic to Improve Patient Knowledge and Satisfaction. J Cancer Educ. 2026 Oct 8. doi: 10.1007/s13187-026-03001-0. Online ahead of print. PubMed 42848271 ↗

Individual participant data

Plan to share: Yes — Only IPD used in the results publication will be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's planned 31 months is below that.

Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2026 → Dec 2027 and completion Apr 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Feb 3, 2025
StartActual
May 5, 2025
Primary completionEst.
Dec 2027was Apr 2026
CompletionEst.
Dec 2027was Apr 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Dec 2027
Oct 14, 2026
Study completion
Apr 2026→Dec 2027
Oct 14, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42848271 ↗
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42848271 ↗
    Primary completion Apr 2026→Dec 2027
    Study completion Apr 2026→Dec 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06805773
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
May 5, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Clinical Trials Manager
Contact
Oncology.Research@sinaihealth.ca
416-586-8440

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion